20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Author:

Bazarbachi Ali1,Labopin Myriam2,Aljurf Mahmoud3,Niittyvuopio Riitta4,Balsat Marie5,Blaise Didier6,Yakoub-Agha Ibrahim7,Grassi Anna8,Reinhardt Hans Christian9ORCID,Lenhoff Stig10,Jindra Pavel11ORCID,Passweg Jakob12,Abou Dalle Iman1,Stadler Michael13,Lioure Bruno14,Ceballos Patrice15,Brissot Eolia2,Giebel Sebastian16,Nagler Arnon17,Schmid Christoph18,Mohty Mohamad2

Affiliation:

1. 1Bone Marrow Transplant Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

2. 2Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, UMR-S938, Paris, France.

3. 3King Faisal Specialist Hospital and Research Centre Oncology (Section of Adult Haematolgy/BMT), Riyadh, Saudi Arabia.

4. 4HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.

5. 5Department of Haematology, Lyon Sud Hospital, Rhône, France.

6. 6Programme de Transplantation and Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.

7. 7CHU de Lille, univ Lille, INSERM U1286, Infinite, Lille, France.

8. 8Hematology and Bone Marrow Transplant Unit, Bergamo, Italy.

9. 9University Hospital, Department of Hematology and Stem Cell Transplantation, Essen, Germany.

10. 10Department of Haematology, Skanes University Hospital, Lund, Sweden.

11. 11Charles University Hospital, Department of Hematology/Oncology, Pilsen, Czech Republic.

12. 12Department of Haematology, University Hospital, Basel, Switzerland.

13. 13Hannover Medical School, Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany.

14. 14Nouvel Hopital Civil, Strasbourg, France.

15. 15Department of Haematology, CHU Lapeyronie, Montpellier, France.

16. 16Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Kr, Gliwice, Poland.

17. 17Chaim Sheba Medical Center, Department of Bone Marrow Transplantation, Tel Hashomer, Israel.

18. 18Universitätsklinikum Augsburg, Augsburg, Germany.

Abstract

Abstract Purpose: Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains the first cause of transplant failure in patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). In other hematologic malignancies, therapeutic advances resulted in significant improvement over time in survival of patients relapsing after transplant. Experimental Design: We compared outcomes at European Society for Blood and Marrow Transplantation (EBMT) participating centers of 899 adult patients with Ph+ ALL who relapsed between 2000 and 2019 after allo-HCT performed in first complete remission. Median follow-up for alive patients was 56 months. Results: Overall, 116 patients relapsed between 2000 and 2004, 225 between 2005 and 2009, 294 between 2010 and 2014, and 264 between 2015 and 2019. Patient and transplant characteristics were similar over the four time periods except for a progressive increase in unrelated donors, peripheral blood stem cells, reduced intensity conditioning, and in vivo T-cell depletion and a progressive decrease in total body irradiation. The 2-year overall survival (OS) after relapse increased from 27.8% for patients relapsing between 2000 and 2004 to 54.8% for 2015 and 2019 (P = 0.001). A second allo-HCT within 2 years after relapse was performed in 13.9% of patients resulting in a 2-year OS of 35.9%. In multivariate analysis, OS from relapse was positively affected by a longer time from transplant to relapse and the year of relapse. Conclusions: We observed a major progressive improvement in OS from posttransplant relapse for patients with Ph+ ALL over the years, likely multifactorial including transplant-related factors, posttransplant salvage, and improvement in supportive care. These large-scale real-world data can serve as a benchmark for future studies in this setting. See related commentary by Gale, p. 813

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3